Study guide
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols
Key Takeaways Explain This Topic AI
Shockable rhythms (VF/pVT) require immediate defibrillation and CPR, with epinephrine 1 mg IV/IO initiated only after the second shock, followed by amiodarone (300 mg then 150 mg) or lidocaine (1 to 1.5 mg/kg then 0.5 to 0.75 mg/kg) for shock-refractory persistence.
Non-shockable rhythms (PEA/Asystole) mandate the earliest possible administration of epinephrine 1 mg IV/IO, repeated every 3 to 5 minutes, accompanied by rapid systematic investigation and treatment of reversible causes (Hs and Ts).
Routine administration of sodium bicarbonate and calcium is not recommended in undifferentiated cardiac arrest; both require specific clinical indications such as severe preexisting metabolic acidosis, hyperkalemia, or toxicologic membrane toxicity.
Magnesium sulfate (1 to 2 g IV/IO push) is indicated exclusively for polymorphic ventricular tachycardia associated with a prolonged QT interval (Torsades de Pointes) or documented severe hypomagnesemia.
Last updated: October 2026
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols
Sudden cardiac arrest represents one of the most critical clinical emergencies encountered by emergency medicine pharmacists. Resuscitation outcomes hinge on high-quality cardiopulmonary resuscitation (CPR), rapid rhythm analysis, timely defibrillation, and evidence-based pharmacotherapeutic interventions. Pharmacists on resuscitation teams must rapidly differentiate between shockable and non-shockable arrest pathways, prepare and administer critical vasoactive and antiarrhythmic agents, anticipate line compatibility challenges, and systematically investigate reversible etiologies.
Rhythm Stratification: Shockable vs. Non-Shockable Pathways
Adult cardiac arrest rhythms fall into two distinct therapeutic categories:
Shockable Rhythms : Ventricular Fibrillation (VF) and Pulseless Ventricular Tachycardia (pVT). The primary intervention is immediate, unsynchronized electrical defibrillation paired with uninterrupted cycles of high-quality CPR (compression rate 100–120 bpm, depth 2–2.4 inches, complete chest recoil, minimizing hands-off time to <10 seconds). Pharmacotherapy serves an adjunctive role to facilitate successful defibrillation and prevent recurrent arrhythmia.
Non-Shockable Rhythms : Pulseless Electrical Activity (PEA) and Asystole. Defibrillation is ineffective and contraindicated. Resuscitation centers on continuous high-quality CPR, early vasoactive support, and rapid identification and reversal of underlying physiological derangements.
Epinephrine Pharmacotherapy & Administration Timing
Epinephrine is the primary vasopressor utilized in adult cardiac arrest. It acts as a non-selective agonist at alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors. In cardiac arrest, its beneficial therapeutic effect is mediated predominantly through alpha-1 adrenergic peripheral vasoconstriction , which elevates systemic vascular resistance, increases aortic diastolic pressure, and augments coronary perfusion pressure (CPP) . A CPP threshold of ≥ 15 to 20 mmHg \ge 15\text{ to }20\text{ mmHg} ≥ 15 to 20 mmHg during resuscitation is strongly correlated with achieving return of spontaneous circulation (ROSC).
Standard Dosing & Route
Dose : 1 mg IV/IO (10 mL of 0.1 mg/mL [1:10,000] solution) administered every 3 to 5 minutes.
Administration : Administer via rapid IV/IO push, immediately followed by a 20 mL 0.9% sodium chloride flush and brief extremity elevation to accelerate central venous transit.
Timing Nuances: Shockable vs. Non-Shockable Rhythms
The clinical timing of initial epinephrine administration differs substantially based on presenting rhythm:
Non-Shockable Rhythms (PEA/Asystole) : Administer epinephrine as soon as vascular access is established . Large observational registries and clinical trial data (including the PARAMEDIC-2 trial) demonstrate that earlier epinephrine administration (within 3 to 5 minutes of arrest onset) is associated with higher rates of ROSC, survival to hospital admission, and survival to hospital discharge in non-shockable arrest.
Shockable Rhythms (VF/pVT) : Withhold epinephrine initially! The first-line interventions are immediate defibrillation and CPR. Epinephrine is administered after the second defibrillation shock (during the second cycle of CPR) if VF/pVT persists, and every 3 to 5 minutes thereafter. Early epinephrine administration before initial shocks can stimulate beta-1 adrenergic receptors, increasing myocardial oxygen consumption, worsening subendocardial ischemia, and triggering recurrent refractory ventricular dysrhythmias.
Important
High-dose epinephrine (e.g., 5 mg boluses or 0.1 mg/kg) is not recommended in routine adult ACLS. Although high doses transiently increase ROSC rates in animal models, human randomized trials demonstrated increased post-ROSC myocardial dysfunction, severe neurological impairment, and zero survival benefit.
Antiarrhythmic Therapy in Shock-Refractory VF/pVT
Antiarrhythmic pharmacotherapy is indicated for shock-refractory VF or pulseless VT —defined as ventricular dysrhythmias that persist or recur after at least two defibrillation shocks and at least one dose of epinephrine.
Amiodarone
Mechanism : Class III antiarrhythmic with broad electropharmacologic effects: blocks potassium outward channels (prolonging action potential duration and effective refractory period), blocks fast inward sodium channels (Class I effect), inhibits L-type calcium channels (Class IV effect), and produces non-competitive alpha- and beta-adrenergic blockade (Class II effect).
ACLS Dosing :
First Dose : 300 mg IV/IO rapid push (diluted in 20 to 30 mL of D5W or 0.9% NaCl, or given undiluted).
Second Dose : 150 mg IV/IO rapid push after 3 to 5 minutes if VF/pVT persists.
Formulation Considerations : Conventional amiodarone intravenous solutions contain polysorbate 80 and benzyl alcohol as solubilizing excipients, which produce peripheral vasodilation and negative inotropy upon ROSC. Aqueous amiodarone formulations (using sulfobutylether beta-cyclodextrin/captisol) eliminate these cosolvent-induced hemodynamic depressions.
Lidocaine
Mechanism : Class Ib antiarrhythmic that selectively binds to and blocks fast inward voltage-gated sodium channels in phase 0 of the cardiac action potential. It preferentially binds to open and inactivated channels in ischemic, depolarized, or rapidly firing ventricular myocardium.
ACLS Dosing :
Initial Bolus : 1 to 1.5 mg/kg IV/IO rapid push.
Repeat Bolus : 0.5 to 0.75 mg/kg IV/IO every 5 to 10 minutes for refractory VF/pVT, up to a maximum cumulative dose of 3 mg/kg .
Post-ROSC Maintenance : 1 to 4 mg/min continuous IV infusion if lidocaine successfully terminated the arrest rhythm.
Amiodarone vs. Lidocaine: The ALPS Trial
The randomized, double-blind ALPS trial (Resuscitation Outcomes Consortium) compared amiodarone, lidocaine, and placebo in adult shock-refractory out-of-hospital cardiac arrest (OHCA). The trial demonstrated that neither amiodarone nor lidocaine showed a statistically significant difference in survival to hospital discharge or favorable neurological outcome compared to placebo overall. However, in the prespecified subgroup of witnessed cardiac arrests , both active antiarrhythmics demonstrated significantly higher rates of hospital survival compared to placebo. The 2025 AHA guidelines state that amiodarone or lidocaine may be considered for shock-refractory VF/pVT (Class 2b); routine calcium, sodium bicarbonate and magnesium are not recommended (Class 3: No Benefit), and steroids are of uncertain benefit.
Summary Matrix: ACLS Cardiac Arrest Pharmacotherapy
Pharmacologic Agent Standard ACLS Dosing Repeat / Maximum Dose Clinical Indication Critical Administration Pearls
Epinephrine 1 mg IV/IO rapid push 1 mg q3–5min (no max ceiling) All arrest rhythms (VF, pVT, PEA, Asystole) Give immediately in PEA/Asystole; defer until after 2nd shock in VF/pVT. Flush with 20 mL saline.
Amiodarone 300 mg IV/IO rapid push 150 mg IV/IO push once after 3–5 min Shock-refractory VF / pulseless VT Administer as rapid push in arrest, NOT slow infusion. Incompatible with sodium bicarbonate.
Lidocaine 1 to 1.5 mg/kg IV/IO push 0.5 to 0.75 mg/kg q5–10min (max 3 mg/kg) Shock-refractory VF / pulseless VT Equivalent to amiodarone in ALPS trial; initiate 1–4 mg/min infusion post-ROSC if effective.
Magnesium Sulfate 1 to 2 g IV/IO push May repeat once in 5–15 min Torsades de Pointes / severe hypomagnesemia Dilute in 10 mL D5W or 0.9% NaCl over 1–2 min. Ineffective for routine undifferentiated VF/pVT.
Sodium Bicarbonate 1 mEq/kg IV/IO push Titrate to blood gas / base deficit Preexisting severe acidosis, hyperkalemia, TCA toxicity Inactivates catecholamines; flush IV lines thoroughly before and after administration.
Calcium Chloride 10% 1 g (10 mL) IV/IO push Repeat q5–10min as clinically indicated Severe hyperkalemia, hypocalcemia, hypermagnesemia, CCB overdose Provides 3x elemental calcium compared to gluconate; preferred formulation in cardiac arrest.
- Targeted Electrolyte and Buffer Therapies
- Magnesium Sulfate
Magnesium acts as an essential cofactor for the sodium-potassium ATPase pump and regulates inward calcium flux through L-type channels. In cardiac arrest, magnesium sulfate is indicated exclusively for Torsades de Pointes (polymorphic VT associated with baseline prolonged QTc) or confirmed severe hypomagnesemia. The recommended dose is 1 to 2 g IV/IO push diluted in 10 mL of D5W or 0.9% NaCl over 1 to 2 minutes. Routine administration in undifferentiated cardiac arrest or monomorphic VF has been evaluated in randomized clinical trials and showed zero improvement in ROSC or hospital survival.
Sodium Bicarbonate
Routine administration of sodium bicarbonate in cardiac arrest is not recommended and may cause significant physiological harm:
Paradoxical Intracellular Acidosis : Exogenous bicarbonate buffers hydrogen ions to produce carbonic acid, which dissociates into water and carbon dioxide ( C O 2 CO_2 C O 2 ). Lipophilic C O 2 CO_2 C O 2 diffuses rapidly across myocardial and cerebral cell membranes, whereas charged bicarbonate remains extracellular, paradoxically worsening intracellular and cerebral acidosis.
Impaired Oxygen Delivery : Alkalinization shifts the oxyhemoglobin dissociation curve to the left, impairing oxygen release at ischemic capillary beds.
Hyperosmolality & Hypernatremia : Standard 8.4% sodium bicarbonate is severely hypertonic (2,000 mOsm/L; 1 mEq/mL sodium and bicarbonate).
Specific Legitimate Indications :
Preexisting documented severe metabolic acidosis (e.g., diabetic ketoacidosis, prolonged downtime with severe lactic acidosis).
Severe preexisting hyperkalemia.
Overdose of sodium-channel blocking medications (tricyclic antidepressants, flecainide, quinidine, cocaine).
Dose : 1 mEq/kg IV/IO push (typically 50 to 100 mEq).
Warning
Sodium bicarbonate must never be infused simultaneously through the same IV line as catecholamines (epinephrine, dopamine, norepinephrine) or calcium salts. Alkaline pH inactivates catecholamines via oxidation and precipitates calcium salts into insoluble calcium carbonate crystals.
Calcium Formulations: Chloride vs. Gluconate
Routine calcium administration in cardiac arrest increases ischemic cell death by exacerbating intracellular calcium overload, activating lytic proteases, and uncoupling mitochondrial oxidative phosphorylation upon reperfusion.
Specific Legitimate Indications :
Documented or strongly suspected severe hyperkalemia.
Severe hypocalcemia (e.g., following massive transfusion secondary to citrate toxicity).
Severe hypermagnesemia.
Severe calcium channel blocker overdose.
Formulation Comparison :
Calcium Chloride 10% : Contains 100 mg/mL of calcium chloride dihydrate ( 1 g = 13.6 mEq = 272 mg 1\text{ g} = 13.6\text{ mEq} = 272\text{ mg} 1 g = 13.6 mEq = 272 mg elemental calcium). Because it delivers more calcium per milliliter, it is usually chosen when calcium is indicated during arrest, through a central line or a well-running large vein.
Calcium Gluconate 10% : Contains 100 mg/mL of calcium gluconate ( 1 g = 4.65 mEq = 93 mg 1\text{ g} = 4.65\text{ mEq} = 93\text{ mg} 1 g = 4.65 mEq = 93 mg elemental calcium), roughly one-third the elemental calcium of the chloride salt per gram, so about 3 g of gluconate matches 1 g of chloride. The old teaching that gluconate needs the liver to release its calcium is wrong: both salts ionize rapidly. Gluconate is preferred for peripheral administration because it is far less irritating if it extravasates.
Reversible Causes: The Hs and Ts Framework
During CPR, the emergency medicine pharmacist must systematically assess and recommend pharmacologic reversals for the reversible causes of arrest:
Loading diagram...
Pharmacotherapy-Specific Reversal Strategies
Hyperkalemia : Calcium chloride 1 g IV push (membrane stabilization) + Sodium bicarbonate 50 to 100 mEq IV push + Regular insulin 10 units IV with 25 g D50W (intracellular shifting).
Local Anesthetic Systemic Toxicity (LAST) : 20% intravenous lipid emulsion (ILE) bolus 1.5 mL/kg over 2 to 3 minutes (about 100 mL in patients over 70 kg), followed by 0.25 mL/kg/min; repeat the bolus and double the infusion to 0.5 mL/kg/min if instability persists, up to about 12 mL/kg (ASRA 2020 checklist).
Suspected Massive Pulmonary Embolism : If cardiac arrest is caused by documented or highly suspected pulmonary embolism, administer intravenous tenecteplase (weight-based bolus) or alteplase (50 mg IV push, may repeat 50 mg in 15 minutes). Once a fibrinolytic is given, continue CPR long enough for it to work: European Resuscitation Council guidance suggests considering 60 to 90 minutes of CPR after fibrinolytic administration.